Combining PD1 inhibitor,PARP inhibitor and antiangiogenic medication for lung squamous cell carcinoma with liver metastasis:a case report  

作　　者：Ruo-Qi Wang Shan-Qi Guo Jun Chen Wen-Yan Fang 

机构地区：[1]Graduate School,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China [2]Department of Oncology,The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300381,China

出　　处：《Precision Medicine Research》2022年第4期1-5,共5页精准医学研究

摘　　要：A 68-year-old man with left chest pain accompanied by chest tightness was reported.The computed tomography revealed a massive liver mass.Genetic and pathological tests confirmed advanced squamous cell lung carcinoma with the mutation of breast cancer susceptibility gene 1 and liver metastasis.The primary lung lesions and local liver metastases were well controlled through combined immunotherapy,antiangiogenic medications and Poly ADP-ribose polymerase inhibitors.Considering the high tumor load and the generally poor condition of the patient,transarterial chemoembolization,in place of the conventional chemotherapy treatment mode was chosed for liver metastasis in the current case.We discussed selecting a tailored program and outlined the patient’s diagnosis and treatment process.Additionally mentioned multiple drug combination strategies for squamous lung cancer.

关 键 词：IMMUNOTHERAPY Programmed cell death protein 1 squamous cell carcinoma Poly ADP-ribose polymerase inhibitors 

分 类 号：R73[医药卫生—肿瘤]